Abstract The Zero Childhood Cancer Program is a precision medicine program to benefit
children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline …

MAPPYACTS (NCT02613962) is an international prospective precision medicine trial
aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory …

Simple Summary Precision medicine is a revolutionary new way to deliver cancer treatment
by targeting specific genetic changes of the cancer of the individual child with the goal of …

To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing
panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective …

Abstract iTHER is a Dutch prospective national precision oncology program aiming to define
tumour molecular profiles in children and adolescents with primary very high-risk, relapsed …

PURPOSE Several studies have indicated that broad genomic characterization of childhood
cancer provides diagnostically and/or therapeutically relevant information in selected high …

Importance Prompt recognition of a child with a cancer predisposition syndrome (CPS) has
implications for cancer management, surveillance, genetic counseling, and cascade testing …

Several cancer predisposition syndromes (CPS) are reported to predispose to
rhabdomyosarcoma, most frequently in children with embryonal rhabdomyosarcoma. There …

Background Germline genome sequencing in childhood cancer precision medicine trials
may reveal pathogenic or likely pathogenic variants in cancer predisposition genes in more …

Biomarkers which better match anticancer drugs with cancer driver genes hold the promise
of improved clinical responses and cure rates. We developed a precision medicine platform …